Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

This study has been completed.
Sponsor:
Collaborators:
The Norwegian Cancer Association
Hoffmann-La Roche
Information provided by:
Haukeland University Hospital
ClinicalTrials.gov Identifier:
NCT00139360
First received: August 30, 2005
Last updated: July 29, 2011
Last verified: July 2011

August 30, 2005
July 29, 2011
May 2005
July 2011   (final data collection date for primary outcome measure)
Clinical Response rates [ Time Frame: continous ] [ Designated as safety issue: No ]
Clinical Response rates
Complete list of historical versions of study NCT00139360 on ClinicalTrials.gov Archive Site
  • Time to progression [ Time Frame: continous ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: continous ] [ Designated as safety issue: No ]
  • Safety data [ Time Frame: continous ] [ Designated as safety issue: Yes ]
  • Time to progression
  • Overall survival
  • Safety data
Not Provided
Not Provided
 
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma and Predictive Value of Angiogenic Markers

To determine the efficacy as measured by objective tumor response of first-line treatment of metastatic melanoma with bevacizumab monotherapy

In Norway, cutaneous malignant melanoma is the second most frequent and the most frequent cancer type in middle-aged (30-54 years) females and males, respectively, and the incidence has six-doubled during the last 30 years. Median survival for patients with metastatic melanoma is 6 months.

Many agents have been investigated for anti-tumor effect in melanoma, but there is no accepted standard therapy. Biochemotherapy, combining cytotoxic drugs with Interleukin-2 or Interferon alpha, has not been shown to be superior to single agent Dacarbazine (DTIC), which is regarded to be the most active agent. Other biological approaches like vaccination are currently under investigation, but still no efficient treatment for metastatic melanoma is available. DTIC induces objective remission in 20% of the patients, but without significant impact on survival.

The need of a new and effective treatment for the group of melanoma patients is urgently needed. This will be the first study to assess response rates of bevacizumab monotherapy in first line treatment of metastatic melanoma. In addition there will be a major focus on the identification of predictive biomarkers of bevacizumab efficacy.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Melanoma
Drug: Bevacizumab
Anti angiogenesis treatment
Experimental: 1
Active drug
Intervention: Drug: Bevacizumab
Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One. 2012;7(6):e38364. doi: 10.1371/journal.pone.0038364. Epub 2012 Jun 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
July 2011
July 2011   (final data collection date for primary outcome measure)

LEVEL A (second line): after confirmed progression on standard first line treatment with dacarbazine.

LEVEL B (first line): when objective clinical response is observed in LEVEL A, patients will be included for first line treatment with bevacizumab

Inclusion Criteria:

  • Histologically confirmed metastatic (unresectable) melanoma and with progressive disease
  • WHO performance status 0-2
  • Age >18 years
  • Able to undergo outpatient treatment
  • Patients must have clinically and/or radiographically documented measurable disease according to RECIST criteria
  • At least 4 weeks since adjuvant interferon alpha
  • Recovered from prior chemotherapy
  • Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start. Biopsy or fine needle aspiration within 5 days prior to study treatment start. Central venous line placement must be inserted at least 5 days prior to treatment start.
  • Minimum required laboratory data:

Hematology: absolute granulocytes > 1.0 x 109/L platelets > 100 x 109/L Biochemistry: bilirubin < 1.5 x upper normal limit serum creatinine within normal limits INR < 1.5

  • Before patient registration/randomization, written informed consent must be given according to national and local regulations.

Exclusion Criteria:

  • No pregnant or lactating patients can be included
  • No prior interferon alpha or IL-2 for metastatic disease
  • No more than 1 prior chemotherapy regimen for metastatic disease
  • No clinical evidence of coagulopathy
  • No brain metastases
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • No history of thrombosis
  • No full-dose oral coumarin-derived anticoagulants (INR>1.5) or heparin, thrombolytic agents, or chronic, daily treatment with aspirin (>325 mg/day)
  • No non-steroidal anti-inflammatory medications (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
  • No uncontrolled hypertension
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00139360
NSD-11933, 94070/013
Not Provided
Oddbjorn Straume, MD, Haukeland University Hospital
Haukeland University Hospital
  • The Norwegian Cancer Association
  • Hoffmann-La Roche
Principal Investigator: Oddbjorn Straume, MD, PhD Department of Oncology, Haukeland University Hospital
Haukeland University Hospital
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP